Roger Lane

10.0k total citations · 2 hit papers
111 papers, 6.4k citations indexed

About

Roger Lane is a scholar working on Pharmacology, Psychiatry and Mental health and Physiology. According to data from OpenAlex, Roger Lane has authored 111 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Pharmacology, 37 papers in Psychiatry and Mental health and 27 papers in Physiology. Recurrent topics in Roger Lane's work include Alzheimer's disease research and treatments (27 papers), Cholinesterase and Neurodegenerative Diseases (27 papers) and Dementia and Cognitive Impairment Research (23 papers). Roger Lane is often cited by papers focused on Alzheimer's disease research and treatments (27 papers), Cholinesterase and Neurodegenerative Diseases (27 papers) and Dementia and Cognitive Impairment Research (23 papers). Roger Lane collaborates with scholars based in United States, United Kingdom and Switzerland. Roger Lane's co-authors include Albert Enz, Steven G. Potkin, Raymond C. Rosen, Matthew Menza, Murat Emre, Sibel Tekin, Martin R. Farlow, David S. Baldwin, Dag Aarsland and Roger Bullock and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and American Journal of Psychiatry.

In The Last Decade

Roger Lane

110 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rivastigmine for Dementia Associated with Parkinson's Disease

2004 793 citations Murat Emre, Dag Aarsland et al. New England Journal of Medicine profile →
Targeting acetylcholinesterase and butyrylcholinesterase in dementia

2005 538 citations Roger Lane et al. profile →

Peers

Countries citing papers authored by Roger Lane

Since Specialization

Citations

This map shows the geographic impact of Roger Lane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger Lane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger Lane more than expected).

Fields of papers citing papers by Roger Lane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger Lane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger Lane. The network helps show where Roger Lane may publish in the future.

Co-authorship network of co-authors of Roger Lane

This figure shows the co-authorship network connecting the top 25 collaborators of Roger Lane. A scholar is included among the top collaborators of Roger Lane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger Lane. Roger Lane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CTAD taskforce: genetic therapies in Alzheimer’s disease 2025 ·The Journal of Prevention of Alzheimer s Disease ·David Jakabek, Adrian M. Isaacs, Bart De Strooper, Mark H. Tuszynski, Roger Lane, (unknown), Eric McDade, Michael S. Rafii, Catherine J. Mummery	1
2	Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers 2024 ·BMC Neurology ·Roger Lane, Taher Darreh‐Shori, Candice Junge, Dan Li, Qingqing Yang, Amanda Edwards, Danielle Graham, Katrina Moore, Catherine J. Mummery	2
3	Functional Glial Activation Mediates Phenotypic Effects of APOEɛ4 and Sex in Alzheimer’s Disease 2024 ·SHILAP Revista de lepidopterología ·Roger Lane, Dan Li, Taher Darreh‐Shori	1
4	Translating Antisense Technology into a Treatment for Huntington’s Disease 2018 ·Methods in molecular biology ·Roger Lane, (unknown), Tiffany Baumann, Marc Gleichmann, Dan Norris, C. Frank Bennett, Holly Kordasiewicz	32
5	Antidepressant drug development: Focus on triple monoamine reuptake inhibition 2014 ·Journal of Psychopharmacology ·Roger Lane	31
6	Restoration of positive mood states in major depression as a potential drug development target 2014 ·Journal of Psychopharmacology ·Roger Lane	7
7	Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach 2009 ·Gender Medicine ·Steven H. Ferris, Roger Lane, Nikolaos Sfikas, Bengt Winblad, Martin R. Farlow, Howard Feldman	21
8	BuChE‐K and APOE ϵ4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline 2008 ·Movement Disorders ·Roger Lane, Yunsheng He, Christopher M. Morris, James B. Leverenz, Murat Emre, Clive Ballard	34
9	Small vessel versus large vessel vascular dementia 2008 ·Journal of Neurology ·Salka S. Staekenborg, Elisabeth C.W. van Straaten, Wiesje M. van der Flier, Roger Lane, Frederik Barkhof, Philip Scheltens	42
10	Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients 2008 ·Movement Disorders ·Paolo Barone, David J. Burn, Teus van Laar, Chuanchieh Hsu, Werner Poewe, Roger Lane	29
11	Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease 2007 ·International Journal of Geriatric Psychiatry ·Bengt Winblad, Ariane K. Kawata, Kathleen Beusterien, Simu K. Thomas, Anders Wimo, Roger Lane, Howard Fillit, Rafael Blesa	86
12	Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease 2006 ·Movement Disorders ·David J. Burn, Murat Emre, Ian G. McKeith, Peter Paul De Deyn, Dag Aarsland, Chuanchieh Hsu, Roger Lane	192
13	Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease 2006 ·Current Medical Research and Opinion ·Roger Bullock, Howard Bergman, Jacques Touchon, Giuseppe Gambina, Yunsheng He, (unknown), Roger Lane	47
14	Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease 2006 ·Pharmacogenetics and Genomics ·Rafael Blesa, Roger Bullock, Yunsheng He, Howard Bergman, Giuseppe Gambina, Joanne M. Meyer, (unknown), (unknown), Roger Lane	49
15	Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias 2006 ·International Journal of Clinical Practice ·Clive Ballard, Roger Lane, Paolo Barone, Roberto Ferrara, Sibel Tekin	30
16	Rivastigmine for Dementia Associated with Parkinson's Disease breakdown → 2004 ·New England Journal of Medicine ·Murat Emre, Dag Aarsland, Alberto Albanese, E. Jane Byrne, Günther Deuschl, Peter Paul De Deyn, Franck Durif, Jaime Kulisevsky, Teus van Laar, Andrew Lees, Werner Poewe, Alain Robillard, Mário Miguel Rosa, Erik Ch. Wolters, Peter Quarg, Sibel Tekin, Roger Lane	793
17	Rivastigmine in Vascular Dementia 2003 ·International Psychogeriatrics ·(unknown), Roger Lane	10
18	RIVASTIGMINE IN PATIENTS WITH ALZHEIMER'S DISEASE AND CONCURRENT HYPERTENSION 2002 ·International Journal of Clinical Practice ·Timo Erkinjuntti, Ingmar Skoog, Roger Lane, (unknown)	29
19	Double-Blind Placebo-Controlled Pilot Study of Sertraline in Military Veterans With Posttraumatic Stress Disorder 2002 ·Journal of Clinical Psychopharmacology ·Joseph Zohar, Daniela Amital, Chanoch Miodownik, Moshe Kotler, Avi Bleich, Roger Lane, Carol D. Austin	157
20	A Randomized Study of Ondansetron Syrup in Children: Evaluation of Taste Acceptability and Tolerance 1996 ·Pediatric Hematology and Oncology ·Richard Stevens, (unknown), Roger Lane, G Schaison	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact